Oncolytics Biotech is trading 5.67% up now at $0.85 after investors digested its second-quarter results, published August 12, 2026.
- Reported a $9.44 million net loss and $0.08 diluted loss per share, versus $5.28 million and $0.06, respectively, a year earlier.
- No new August 14 company announcement or explicit explanation for the intraday gain was identified; broader markets were modestly lower, suggesting the move was primarily company-specific.